Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-08-02

Clinical Trial Update: Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms [Phase 3]

View source ↗

Summary

Phase 3 trial update on MCS-2 for lower urinary tract symptoms and benign prostatic hyperplasia reports efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MCS-2

Snippet

Sponsor: Health Ever Bio-Tech Co., Ltd. | Conditions: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 3 | Status: COMPLETED